Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2– Metastatic Breast Cancer From the US and Chinese Perspectives
Zhang, Yingjie, Zeng, Xiaohui, Deng, Haijun, Ma, Fang, Peng, Ye, Yi, Lidan, Tan, Chongqing, Peng, LiubaoJournal:
Clinical Therapeutics
DOI:
10.1016/j.clinthera.2019.04.033
Date:
May, 2019
File:
PDF, 1.49 MB
2019
File converter
More search results
More benefits 
